ABOUT US
The AGP Difference
Differentiated Strategy
which gives exposure via both funds (50%) and directs (50%)
Disrupting Old Practices
by using a Techonology and Data-driven approach
Investment Team
with a strong pedigree in both Life Sciences as well as Investments
Global Footprint
with a presence in San Francisco, Boston, NewYork, London, Riyadh, Dubai, Mumbai and Taipei.
Why Early-Stage Life Science?
Sector at an infection point and poised for major disruption
Biggest wealth creation opportunity during our lifetime
Last few decades were all about technology, next few decades would be about life sciences
Strong government support with non-dilutive grants
Early stage gets less than 5% of the total private funding for this sector
Robust biopharma exit market with average years to exit of 3.5 years for M&A transactions
Sector at an infection point and poised for major disruption
Biggest wealth creation opportunity during our lifetime
Last few decades were all about technology, next few decades would be about life sciences
Strong government support with non-dilutive grants
Early stage gets less than 5% of the total private funding for this sector
Robust biopharma exit market with average years to exit of 3.5 years for M&A transactions
At Inflection Point
Old Practices
Slow, Reactive, Biased
-
Little real-time data
-
Does not support prevention
-
Not patient centric experience
-
Mass generalization
-
Complex regulations
Future Practices
Predictive, Preventive, Real-time
-
Real-time data
-
Predictive and preventive approach
-
Personalized & customization
-
AI, machine learning, cloud based
-
Digitalization of clinical